Skip to content

Study · Measured the body's own peptide · 1994

3 results

Distribution of vasoactive intestinal peptide (VIP) and its binding sites in labial salivary glands in Sjögren's syndrome and in normal controls.

Törnwall J, Uusitalo H, Hukkanen M, Sorsa T, Konttinen YT

Clinical and experimental rheumatology1 May 1994Cited by 19 (Europe PMC)

PMID8070162 (opens in a new tab)PepBankPUB-08070162
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In labial salivary glands of patients with Sjögren's syndrome, VIP-containing nerves surrounded acini, ducts, blood vessels and deep parenchyma but were absent from large inflammatory cell foci.

    In plain wordsIn people with Sjögren's syndrome, the body's own VIP nerves were found around salivary gland structures but not in large inflamed areas.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableDistribution of VIP-containing nerves in labial salivary glands in Sjögren's syndrome
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Immune and inflammation

    Source sentences

    Summary
    VIP-containing nerves were seen around salivary acini, salivary ducts, blood vessels and deep parenchyma, but were absent from large inflammatory cell foci in patients with Sjögren's syndrome.
    2 context sentences
    Summary · context
    Tissue distribution of vasoactive intestinal peptide (VIP)-containing nerves and their target cells were studied in labial salivary glands in patients with Sjögren's syndrome and in healthy controls.
    Summary · context
    Immunoperoxidase staining was used to demonstrate VIP-containing nerve fibers, and receptor autoradiography with 125I-Bolton Hunter (BH)-VIP was used to demonstrate VIP positive binding sites.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 02HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyOther

    Receptor autoradiography with labelled VIP showed VIP binding sites on mucous acinar cells and blood vessels, and none on salivary ducts.

    In plain wordsIn salivary gland tissue, VIP receptor sites were found on mucus-producing cells and blood vessels, but not on ducts.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP binding sites in labial salivary glands (receptor autoradiography)
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Immune and inflammation

    Source sentences

    Summary
    Receptor autoradiography with 125I-BH-VIP disclosed VIP binding sites on mucous acinar cells and blood vessels, whereas salivary ducts contained no VIP receptors.
    2 context sentences
    Summary · context
    Tissue distribution of vasoactive intestinal peptide (VIP)-containing nerves and their target cells were studied in labial salivary glands in patients with Sjögren's syndrome and in healthy controls.
    Summary · context
    Immunoperoxidase staining was used to demonstrate VIP-containing nerve fibers, and receptor autoradiography with 125I-Bolton Hunter (BH)-VIP was used to demonstrate VIP positive binding sites.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 03HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyOther

    In salivary gland tissue of patients with Sjögren's syndrome, VIP binding sites were absent from the centers of large inflammatory cell foci and acinar atrophy.

    In plain wordsIn people with Sjögren's syndrome, VIP receptor sites were missing from the centers of large inflamed areas of the salivary gland.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP binding sites in inflammatory foci
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Immune and inflammation

    Source sentences

    Summary
    VIP binding sites were also absent from the centers of large inflammatory cell foci/acinar atrophy.
    2 context sentences
    Summary · context
    Tissue distribution of vasoactive intestinal peptide (VIP)-containing nerves and their target cells were studied in labial salivary glands in patients with Sjögren's syndrome and in healthy controls.
    Summary · context
    Immunoperoxidase staining was used to demonstrate VIP-containing nerve fibers, and receptor autoradiography with 125I-Bolton Hunter (BH)-VIP was used to demonstrate VIP positive binding sites.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.